Your search returned 7 results.

Sort
Results
1.
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia with human epidermal growth factor receptor 2-positive metastatic breast cancer: results from the phase III trial CLEOPATRA. MedStar authors:
  • Swain, Sandra M
PMID:
  • 24869931
Year: 2014
Citation:
  • Oncologist. 19(7):693-701, 2014 Jul.
Institution:
  • Washington Cancer Institute
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Chan V, Clark E, Im SA, Im YH, Knott A, Miles D, Ross G, Swain SM
2.
Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA). MedStar authors:
  • Swain, Sandra M
PMID:
  • 24129974
Year: 2013
Citation:
  • Breast Cancer Research & Treatment. 142(1):89-99, 2013 Nov.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Amadori D, Baselga J, Clark E, Knott A, Miles D, Ross G, Semiglazov V, Sunpaweravong P, Swain SM
3.
Twenty-five year results of the national cancer institute randomized breast conservation trial. MedStar authors:
  • Swain, Sandra M
PMID:
  • 22113254
Year: 2012
Citation:
  • Breast Cancer Research & Treatment. 132(1):197-203, 2012 Feb.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Camphausen K, Dan T, Danforth DN, Glatstein E, Lippman ME, Lita E, Sciuto L, Shih J, Simone NL, Smith SL, Swain SM
4.
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. [Review] MedStar authors:
  • Swain, Sandra M
PMID:
  • 24529560
Year: 2014
Citation:
  • Lancet. 384(9938):164-72, 2014 Jul 12.
Medline publication type:
  • Journal Article
  • Meta-Analysis
  • Research Support, U.S. Gov't, P.H.S.
  • Review
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Bergh J, Blohmer J, Blumenthal G, Bogaerts J, Bonnefoi H, Cameron D, Cortazar P, Costantino JP, Ditsch N, Eidtmann H, Eiermann W, Fasching PA, Gerber B, Geyer CE Jr, Gianni L, Justice R, Loibl S, Mamounas EP, Mehta K, Paik S, Pazdur R, Perou C, Piccart M, Prowell T, Rastogi P, Semiglazov V, Slaets L, Sridhara R, Swain SM, Tang S, Untch M, Valagussa P, von Minckwitz G, Wickerham DL, Wolmark N, Zhang L
5.
Bevacizumab added to neoadjuvant chemotherapy for breast cancer. MedStar authors:
  • Swain, Sandra M
PMID:
  • 22276821
Year: 2012
Citation:
  • New England Journal of Medicine. 366(4):310-20, 2012 Jan 26.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
Form of publication:
  • Journal Article
All authors:
  • Adams PT, Atkins JN, Baez-Diaz L, Bear HD, Brufsky AM, Costantino JP, Fehrenbacher L, Gaur R, Geyer CE Jr, Gross HM, Mamounas EP, Margolese RG, Mehta RS, Rastogi P, Robidoux A, Senecal FM, Swain SM, Tang G, Wolmark N, Young JA
6.
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. MedStar authors:
  • Swain, Sandra M
PMID:
  • 23602601
Year: 2013
Citation:
  • Lancet Oncology. 14(6):461-71, 2013 May.
Institution:
  • Washington Cancer Institute
Medline publication type:
  • Clinical Trial, Phase III
  • Journal Article
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
Form of publication:
  • Journal Article
All authors:
  • Baselga J, Benyunes MC, Campone M, Ciruelos E, Clark E, Cortes J, Ferrero JM, Kim SB, Knott A, Ro J, Ross G, Schneeweiss A, Semiglazov V, Swain SM
7.
Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. MedStar authors:
  • Asch, Federico M
  • Barac, Ana
  • Cunningham, A
  • Gallagher, Christopher
  • Hofmeyer, Mark
  • Srichai, M B
  • Swain, Sandra M
PMID:
  • 30852761
Year: 2019
Citation:
  • Breast Cancer Research & Treatment. 175(3):595-603, 2019 Jun.
Institution:
  • MedStar Health
  • MedStar Health Research Institute
  • MedStar Heart & Vascular Institute
  • Washington Cancer Institute
Department:
  • Associate Dean for Research Development
Medline publication type:
  • Journal Article
Form of publication:
  • Journal Article
All authors:
  • Asch FM, Barac A, Cunningham A, Dang C, Gallagher C, Geng X, Herbolsheimer P, Hofmeyer M, Isaacs C, Lynce F, Nunes R, Pohlmann PR, Shajahan-Haq A, Smith KL, Srichai MB, Swain SM, Tan MT, Timothee P, Warren R, Yu AF
Pages

Powered by Koha